Jeffry Wahl, MD
Family Medicine · Harmony, PANPI 1063417087
Payments from drug & device makers
Across 831 payments — averaging $15.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AbbVie$2K
- Pfizer$1K
- Novo Nordisk$1K
- Daiichi Sankyo Inc.$1K
- Johnson & Johnson$644
- plus $4K from 30 others
What the payments were for
- Food & beverage$12,509100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 141 | $2,179 |
| AbbVie(2 entities) | 141 | $1,914 |
| Pfizer | 94 | $1,315 |
| Novo Nordisk | 90 | $1,275 |
| Daiichi Sankyo Inc. | 52 | $1,133 |
| Johnson & Johnson | 43 | $644 |
| Amgen | 43 | $625 |
| Novartis | 41 | $582 |
| Lilly USA, LLC | 23 | $386 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $367 |
| E.r. Squibb & Sons, L.L.C. | 19 | $282 |
| Amarin Pharma, Inc. | 17 | $237 |
| Exact Sciences | 12 | $199 |
| Merck | 15 | $198 |
| Shield Therapeutics Inc | 10 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $150 |
| Bayer | 8 | $136 |
| Grifols USA, LLC | 5 | $80 |
| Esperion Therapeutics, Inc. | 5 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $68 |
| Biohaven Pharmaceuticals, Inc. | 5 | $68 |
| Sanofi Pasteur Inc. | 3 | $52 |
| AstraZeneca | 3 | $45 |
| Boehringer Ingelheim | 3 | $45 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Abbott | 3 | $38 |
| Edwards Lifesciences | 2 | $33 |
| Heartflow, Inc. | 2 | $31 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $28 |
| Inari Medical, Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Metuchen Pharmaceuticals | 1 | $14 |
| Bristol Myers Squibb | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$124
- INJECTAFER$108
How this compares
$12,509 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 197 | $190,048 |
| JardianceEmpagliflozin | 128 | $114,470 |
| XareltoRivaroxaban | 80 | $87,964 |
| JanuviaSitagliptin Phosphate | 82 | $75,428 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $72,891 |
| EntrestoSacubitril/Valsartan | 49 | $66,307 |
| OzempicSemaglutide | 43 | $58,894 |
| Teriflunomide | 12 | $35,104 |
| Repatha SureclickEvolocumab | 42 | $34,930 |
| NeurontinGabapentin | 13 | $29,553 |
| ViberziEluxadoline | 13 | $21,515 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $16,661 |
| MyrbetriqMirabegron | 23 | $16,447 |
| BrilintaTicagrelor | 20 | $10,467 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $9,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,315 | $190,048197 claims |
| Boehringer IngelheimJardiance | $45 | $114,470128 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,179 | $89,552128 claims |
| Johnson & JohnsonXarelto | $644 | $87,96480 claims |
| MerckJanuvia | $198 | $75,42882 claims |
| NovartisEntresto | $582 | $66,30749 claims |
| Novo NordiskOzempic | $1,275 | $58,89443 claims |
| AbbVieViberzi | $1,914 | $21,51513 claims |
| Astellas Pharma US IncMyrbetriq | $28 | $16,44723 claims |
| AstraZenecaBrilinta | $45 | $10,46720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Harmony
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.